American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.

PURPOSE To provide updated American Brachytherapy Society (ABS) guidelines for transrectal ultrasound-guided transperineal interstitial permanent prostate brachytherapy (PPB). METHODS AND MATERIALS The ABS formed a committee of brachytherapists and researchers experienced in the clinical practice of PPB to formulate updated guidelines for this technique. Sources of input for these guidelines included prior published guidelines, clinical trials, published literature, and experience of the committee. The recommendations of the committee were reviewed and approved by the Board of Directors of the ABS. RESULTS Patients with high probability of organ-confined disease or limited extraprostatic extension are considered appropriate candidates for PPB monotherapy. Low-risk patients may be treated with PPB alone without the need for supplemental external beam radiotherapy. High-risk patients should receive supplemental external beam radiotherapy if PPB is used. Intermediate-risk patients should be considered on an individual case basis. Intermediate-risk patients with favorable features may appropriately be treated with PPB monotherapy but results from confirmatory clinical trials are pending. Computed tomography-based postimplant dosimetry performed within 60 days of the implant is considered essential for maintenance of a satisfactory quality assurance program. Postimplant computed tomography-magnetic resonance image fusion is viewed as useful, but not mandatory. CONCLUSIONS Updated guidelines for patient selection, workup, treatment, postimplant dosimetry, and followup are provided. These recommendations are intended to be advisory in nature with the ultimate responsibility for the care of the patients resting with the treating physicians.

[1]  J. Koziol,et al.  Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. , 2004, Brachytherapy.

[2]  Dan Ash,et al.  The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[3]  José Pérez-Calatayud,et al.  Dosimetric prerequisites for routine clinical use of photon emitting brachytherapy sources with average energy higher than 50 kev. , 2007, Medical physics.

[4]  K. Wallner,et al.  Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. , 2006, Brachytherapy.

[5]  Ivan Yeung,et al.  Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. , 2002, Brachytherapy.

[6]  R. Stock,et al.  The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. , 2007, The Journal of urology.

[7]  K. Wallner,et al.  Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. , 2007, International journal of radiation oncology, biology, physics.

[8]  D. Theodorescu,et al.  Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience. , 2005, The Journal of urology.

[9]  R. Stock,et al.  Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. , 1995, Techniques in urology.

[10]  J. Sylvester,et al.  Analysis of the Pro-Qura Database: rectal dose, implant quality, and brachytherapist's experience. , 2009, Brachytherapy.

[11]  J. Eichling,et al.  Radiation exposure to family and household members after prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[12]  K. Wallner,et al.  Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. , 2007, Urology.

[13]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2003, Medical physics.

[14]  T. Krupski,et al.  Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. , 2001, The Journal of urology.

[15]  J J Prete,et al.  Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. , 1998, Radiology.

[16]  Grado Gl Techniques to achieve optimal seed placement in salvage and primary brachytherapy for prostate cancer. , 2000 .

[17]  H. Sandler,et al.  A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. , 2006, Brachytherapy.

[18]  A. Dicker,et al.  Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. , 2001, International journal of radiation oncology, biology, physics.

[19]  J. Blasko,et al.  Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. , 2002, Seminars in radiation oncology.

[20]  W. Butler,et al.  Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. , 1998, Radiation oncology investigations.

[21]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.

[22]  Stone Nn,et al.  Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. , 2000 .

[23]  J. Blasko,et al.  Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[24]  K. Wallner,et al.  Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. , 2004, International journal of radiation oncology, biology, physics.

[25]  L. Potters,et al.  Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. , 2006, International journal of radiation oncology, biology, physics.

[26]  F. Critz,et al.  10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. , 2004, The Journal of urology.

[27]  Joseph Bucci,et al.  Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? , 2006, International journal of radiation oncology, biology, physics.

[28]  Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. , 2004, International journal of radiation oncology, biology, physics.

[29]  B. Carey,et al.  Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[30]  W Cavanagh,et al.  Use of TRUS to predict pubic arch interference of prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[31]  D. Ash,et al.  ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  William Cavanagh,et al.  A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. , 2007, Brachytherapy.

[33]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[34]  E. B. Butler,et al.  Predictors of Extracapsular Extension and Its Radial Distance in Prostate Cancer: Implications for Prostate IMRT, Brachytherapy, and Surgery , 2003, Cancer journal.

[35]  B. Davis,et al.  Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression , 2004, Cancer journal.

[36]  Blasko,et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[37]  R. Stock,et al.  Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. , 2000, Techniques in urology.

[38]  T. Solberg,et al.  Improvements in prostate brachytherapy dosimetry due to seed stranding. , 2007, Brachytherapy.

[39]  J. Blasko,et al.  Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry. , 2007, Brachytherapy.

[40]  D. Bostwick,et al.  Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary? , 2000, Techniques in urology.

[41]  S Nag,et al.  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. , 2000, International journal of radiation oncology, biology, physics.

[42]  H. Hoshi,et al.  Migration of prostate brachytherapy seeds to the vertebral venous plexus. , 2006, Brachytherapy.

[43]  Ravinder Nath,et al.  Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy. , 2005, Medical physics.

[44]  H. Sandler,et al.  Late toxicity and biochemical recurrence after external‐beam radiotherapy combined with permanent‐source prostate brachytherapy , 2007, Cancer.

[45]  J. Blasko,et al.  Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. , 2005, Brachytherapy.

[46]  W. Butler,et al.  AAPM Recommendations on Dose Prescription and Reporting Methods for Permanent Interstitial Brachytherapy for Prostate Cancer Report of AAPMTask Group , 2009 .

[47]  J. Blasko,et al.  Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. , 2002, International journal of radiation oncology, biology, physics.

[48]  S. Chiu‐Tsao,et al.  Thermoluminescent dosimetry of the SourceTech Medical model STM1251 125I seed. , 2003, Medical physics.

[49]  American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. , 2000, International journal of radiation oncology, biology, physics.

[50]  J. Sylvester,et al.  Inter-institutional variation of implant activity for permanent prostate brachytherapy. , 2008, Brachytherapy.

[51]  Roberto Orecchia,et al.  MR and CT image fusion for postimplant analysis in permanent prostate seed implants. , 2004, International journal of radiation oncology, biology, physics.

[52]  P. Unger,et al.  Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. , 1996, Urology.

[53]  J. Sylvester,et al.  Optimal Equations for Describing the Relationship Between Prostate Volume, Number of Sources, and Total Activity in Permanent Prostate Brachytherapy , 2009, American journal of clinical oncology.

[54]  A. Dicker,et al.  Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: can implant quality be predicted on day 0? , 2002, International journal of radiation oncology, biology, physics.

[55]  Mark J Rivard,et al.  Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group. , 2008, Brachytherapy.

[56]  Michael W Kattan,et al.  Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. , 2007, International journal of radiation oncology, biology, physics.

[57]  P. Clark,et al.  Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? , 2005, Brachytherapy.

[58]  K. Wallner,et al.  Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. , 2007, International journal of radiation oncology, biology, physics.

[59]  D. Beyer,et al.  Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[60]  F. Vicini,et al.  The influence of percentage of preradiation needle biopsies with adenocarcinoma and total radiation dose on the pathologic response of unfavorable prostate adenocarcinoma. , 2002, American journal of clinical pathology.

[61]  G. Pond,et al.  Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. , 2006, International journal of radiation oncology, biology, physics.

[62]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[63]  Jeremy L Millar,et al.  Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[64]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[65]  J. Cheville,et al.  Permanent prostate brachytherapy: pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. , 2006, Urology.

[66]  Ravinder Nath,et al.  American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy , 2000 .

[67]  A. Cantor,et al.  103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. , 2005, Brachytherapy.

[68]  D W Hillman,et al.  The radial distance of extraprostatic extension of prostate carcinoma , 1999, Cancer.

[69]  W. Butler,et al.  Seed fixity in the prostate/periprostatic region following brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[70]  R. Stock,et al.  Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. , 2007, Brachytherapy.

[71]  P. Young,et al.  Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. , 2004, Mayo Clinic proceedings.

[72]  A. D'Amico,et al.  Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. , 2005, Urology.

[73]  T. Skolarus,et al.  The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer , 2007, Nature Clinical Practice Urology.

[74]  P. Carroll,et al.  Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy. , 2000, Urology.

[75]  B. Davis,et al.  Prostate brachytherapy seed migration to a coronary artery found during angiography. , 2002, The Journal of urology.

[76]  Masayuki Matsuo,et al.  Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostate brachytherapy. , 2006, International journal of radiation oncology, biology, physics.

[77]  W Cavanagh,et al.  Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[78]  D. Yan,et al.  Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? , 2004, International journal of radiation oncology, biology, physics.

[79]  S. Schild,et al.  Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[80]  W. J. Morris,et al.  Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[81]  T W Griffin,et al.  Reduction of radioactive seed embolization to the lung following prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[82]  K. Wallner,et al.  Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[83]  P. Grimm,et al.  A survey of current clinical practice of permanent prostate brachytherapy in the United States. , 1998, International journal of radiation oncology, biology, physics.

[84]  N. Shigematsu,et al.  Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy. , 2007, Brachytherapy.

[85]  R Nath,et al.  Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants. , 1999, International journal of radiation oncology, biology, physics.

[86]  K. Wallner,et al.  Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. , 1997, International journal of radiation oncology, biology, physics.

[87]  H. Sandler,et al.  Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. , 2005, International journal of radiation oncology, biology, physics.

[88]  L. Potters,et al.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[89]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[90]  P. Clark,et al.  Dosimetric Quantifiers for Low Dose Rate Prostate Brachytherapy: V100 Is Superior to D90 , 2005 .

[91]  Ismail B. Tutar,et al.  Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality. , 2007, International journal of radiation oncology, biology, physics.

[92]  N Lee,et al.  Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[93]  E. Small,et al.  Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. , 2008, International journal of radiation oncology, biology, physics.

[94]  Ann L Oberg,et al.  Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. , 2004, International journal of radiation oncology, biology, physics.

[95]  H. Sandler,et al.  A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. , 2006, International journal of radiation oncology, biology, physics.

[96]  J. Blasko,et al.  Radiation safety parameters following prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[97]  David Beyer,et al.  Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. , 2002, International journal of radiation oncology, biology, physics.

[98]  G. Lockwood,et al.  Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[99]  K. Wallner,et al.  The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. , 2002, International journal of radiation oncology, biology, physics.

[100]  P. Walsh Predictive factors of urinary retention following prostate brachytherapy. , 2003, The Journal of urology.

[101]  H. Holm The history of interstitial brachytherapy of prostatic cancer. , 1997, Seminars in surgical oncology.

[102]  W. Lee,et al.  Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. , 2000, International journal of radiation oncology, biology, physics.

[103]  J. Ciezki,et al.  Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. , 2005, International journal of radiation oncology, biology, physics.

[104]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[105]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[106]  R. Stock,et al.  Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation , 2006, BJU international.

[107]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[108]  S. Schild,et al.  Prostate brachytherapy seed embolization to the right renal artery. , 2009, Brachytherapy.

[109]  W. Cavanagh,et al.  Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPIDStrand: a dosimetric analysis. , 2004, Brachytherapy.

[110]  Robert W Galbreath,et al.  15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. , 2007, International journal of radiation oncology, biology, physics.

[111]  L. Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[112]  W. Butler,et al.  Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[113]  W. J. Morris,et al.  Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? , 2010, Brachytherapy.

[114]  D. Raben,et al.  Effects of pelvic rotation and needle angle on pubic arch interference during transperineal prostate implants. , 2000, International journal of radiation oncology, biology, physics.

[115]  A. Zietman,et al.  Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[116]  M. Keyes,et al.  Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy. , 2008, International journal of radiation oncology, biology, physics.

[117]  Y. Yu,et al.  Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. , 2001, International journal of radiation oncology, biology, physics.

[118]  N. Yue,et al.  Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. , 1998, International Journal of Radiation Oncology, Biology, Physics.

[119]  Nawaid Usmani,et al.  Lack of significant intraprostatic migration of stranded iodine-125 sources in prostate brachytherapy implants. , 2011, Brachytherapy.

[120]  M. Kattan,et al.  Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.

[121]  J. Battermann,et al.  The learning curve in prostate seed implantation. , 2000, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[122]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  K. Wallner,et al.  Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[124]  K. Shinohara,et al.  Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: Our experience and literature review , 2009, International journal of urology : official journal of the Japanese Urological Association.

[125]  G. Pond,et al.  Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. , 2006, Brachytherapy.

[126]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[127]  Jette Borg,et al.  Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy. , 2010, International journal of radiation oncology, biology, physics.

[128]  A. Henderson,et al.  Identification of pubic arch interference in prostate brachytherapy: simplifying the transrectal ultrasound technique. , 2003, Brachytherapy.

[129]  J. Oesterling,et al.  A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. , 1997, The Journal of urology.

[130]  H. Levin,et al.  Extent of extracapsular extension in localized prostate cancer. , 2000, Urology.

[131]  Ivan Yeung,et al.  MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy. , 2004, Brachytherapy.

[132]  K. Charyulu Transperineal interstitial implantation of prostate cancer: a new method. , 1980, International journal of radiation oncology, biology, physics.

[133]  Louis Potters,et al.  Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. , 2007, International journal of radiation oncology, biology, physics.

[134]  Patrick W McLaughlin,et al.  Randomized trial of high- and low-source strength (125)I prostate seed implants. , 2005, International journal of radiation oncology, biology, physics.

[135]  G. Glasgow,et al.  Effect of prostatic edema on CT-based postimplant dosimetry. , 2002, International journal of radiation oncology, biology, physics.

[136]  K. Wallner,et al.  Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. , 2003, Urology.

[137]  J. Crook,et al.  Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  R. Stock,et al.  Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. , 1999, International journal of radiation oncology, biology, physics.

[139]  J. Blasko,et al.  Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. , 2007, Brachytherapy.

[140]  F M Waterman,et al.  Effect of post-implant edema on the rectal dose in prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[141]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[142]  J. Cheville,et al.  Histopathologic characterization of seminal vesicle invasion in prostate cancer: implications for radiotherapeutic management , 2001 .

[143]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[144]  W. Cavanagh,et al.  The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. , 2003, International journal of radiation oncology, biology, physics.

[145]  J. Pow-Sang,et al.  A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. , 2006, Brachytherapy.

[146]  K. Wallner,et al.  American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[147]  Yan Yu,et al.  A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning in prostate (125)I seed implantation. , 2010, Brachytherapy.

[148]  B. Davis,et al.  Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. , 2000, The Journal of urology.

[149]  K. Wallner,et al.  Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. , 2003, The Journal of urology.

[150]  L. Potters,et al.  Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. , 2005, Brachytherapy.

[151]  I. Kaplan,et al.  Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. , 2007, Brachytherapy.

[152]  K. Wallner,et al.  Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy , 2006, BJU international.

[153]  K. Wallner,et al.  Local anesthesia for prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[154]  C. Catton,et al.  Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. , 2002, International journal of radiation oncology, biology, physics.

[155]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[156]  R. Stock,et al.  Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. , 2005, The Journal of urology.

[157]  A. Hanlon,et al.  The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. , 2004, International journal of radiation oncology, biology, physics.

[158]  Sushil Beriwal,et al.  Overcoming pubic arch interference with free-hand needle placement in men undergoing prostate brachytherapy. , 2009, Brachytherapy.

[159]  M. Thoulouzan,et al.  Ejaculatory function after permanent 125I prostate brachytherapy for localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[160]  F. Vicini,et al.  Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. , 2002, The Journal of urology.

[161]  B. Jacobs,et al.  Dosimetric outcomes in prostate brachytherapy: is downsizing the prostate with androgen deprivation necessary? , 2009, Brachytherapy.

[162]  K. Wallner,et al.  Prostate brachytherapy in obese patients. , 2002, Brachytherapy.

[163]  K. Wallner,et al.  Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. , 2005, Urology.